2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 142 filers reported holding 2SEVENTY BIO INC in Q3 2023. The put-call ratio across all filers is 3.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,617,286 | -29.6% | 412,573 | +81.6% | 0.00% | – |
| Q2 2023 | $2,298,819 | -90.6% | 227,156 | -90.5% | 0.00% | -100.0% |
| Q1 2023 | $24,420,697 | +703.8% | 2,394,186 | +638.4% | 0.01% | +400.0% |
| Q4 2022 | $3,038,260 | +29.3% | 324,254 | +100.8% | 0.00% | – |
| Q3 2022 | $2,350,000 | +38.0% | 161,492 | +25.2% | 0.00% | – |
| Q2 2022 | $1,703,000 | +331.1% | 129,035 | +457.8% | 0.00% | – |
| Q1 2022 | $395,000 | -75.6% | 23,133 | -63.4% | 0.00% | – |
| Q4 2021 | $1,619,000 | – | 63,162 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Newtyn Management, LLC | 1,587,805 | $27,088,000 | 6.49% |
| CHI Advisors LLC | 819,672 | $13,984,000 | 5.95% |
| Madison Avenue Partners, LP | 896,972 | $15,302,342,000 | 2.86% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $24,036,000 | 2.33% |
| EcoR1 Capital, LLC | 3,495,943 | $59,641,000 | 1.87% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $5,118,000 | 1.02% |
| CVI Holdings, LLC | 819,672 | $13,984,000 | 0.92% |
| ARMISTICE CAPITAL, LLC | 2,000,000 | $34,120,000 | 0.66% |
| Altium Capital Management LP | 115,000 | $1,962,000 | 0.66% |
| Casdin Capital, LLC | 614,754 | $10,488,000 | 0.47% |